Letybo

Botulinum toxin type A, the active ingredient in Letybo, is a botulinum toxin presented as a sterile injectable for intramuscular use. It temporarily reduces muscle overactivity and is employed in the management of several neuromuscular disorders in adult patients.

GNH USA supplies Letybo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Letybo is a botulinum toxin type A used to treat disorders characterized by excessive muscle activity. - Cervical dystonia: reduces abnormal neck muscle contractions, improving posture and pain. - Blepharospasm: lessens involuntary eyelid closure, enhancing visual function. - Upper‑limb spasticity: decreases muscle tone, facilitating movement and rehabilitation. - Chronic migraine: lowers frequency of migraine days when injected in specific head muscles. - Primary axillary hyperhidrosis: diminishes excessive sweating by blocking sympathetic nerve signals.

Adverse reactions may occur following intramuscular injection of Letybo.

Common Side Effects: - Injection site pain or bruising. - Headache. - Flu‑like symptoms. - Mild localized weakness. - Dry mouth. - Transient vision changes.

Serious or Rare Side Effects: - Dysphagia or difficulty swallowing. - Respiratory compromise or apnea. - Botulism‑like systemic spread. - Severe allergic reaction (anaphylaxis). - Unintended muscle weakness distant from injection site. - Vision loss or double vision.

Prior to administration, clinicians should assess patient history and comorbidities. - Contraindications: active infection at injection site or known hypersensitivity to botulinum toxin. - Caution in patients with neuromuscular disorders such as myasthenia gravis. - Avoid concurrent use of other botulinum toxin products. - Monitor for signs of systemic toxin spread, especially in the first weeks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Botulinum toxin type A may interact with several medication classes.

Major Interactions (Avoid): - Aminoglycoside antibiotics (e.g., gentamicin). - Quinine or quinidine. - Cyclosporine. - Other botulinum toxin preparations. - Cholinesterase inhibitors (e.g., pyridostigmine).

Moderate Interactions (Monitor Closely): - Systemic muscle relaxants. - Anticholinergic agents. - Beta‑blockers. - Calcium channel blockers. - Diuretics that may alter electrolyte balance.